4

PRIMARY DOCUMENT

Company: REGENERON PHARMACEUTICALS, INC.
Filed: March 29, 2023
Period of Report: March 27, 2023
Accession Number: 0001968202-23-000004

View Document ↗ View on SEC.gov ↗